Biogen launches weekly LEQEMBI IQLIK Alzheimer’s treatment in US

• Biogen and Eisai announced U.S. availability of LEQEMBI IQLIK, a once-weekly subcutaneous treatment for early Alzheimer’s disease.
• The treatment delivers 500 mg once weekly during initiation and may transition to 360 mg weekly maintenance after 18 months.
• The companies stated that the option may allow at-home dosing and fewer clinic visits compared with infusion-based treatment.

Biogen (NASDAQ:BIIB) and Eisai announced that LEQEMBI IQLIK, a once-weekly subcutaneous lecanemab-irmb autoinjector, is now available in the United States for adults with early Alzheimer’s disease.

The treatment is approved for initiation therapy in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease and provides an alternative administration route to intravenous infusion.

LEQEMBI IQLIK delivers 500 mg once weekly through two consecutive 250 mg injections during initiation and may be used for 360 mg weekly maintenance after 18 months of intravenous or subcutaneous treatment.

The companies stated that patients can continue treatment through either intravenous infusion or subcutaneous injection.

Biogen and Eisai are providing patient support resources including an Instructions for Use video, IQLIK Welcome Kit, LEQEMBI Companion app, specialty pharmacy support, and assistance programs for eligible uninsured patients.

LEQEMBI is a medicine developed for early Alzheimer’s disease, with treatment options focused on reducing amyloid beta plaques associated with the progression of the disease.